TOKYO -- Japan's national medical insurance system was given the go-ahead on Wednesday to cover leukemia treatment using expensive Kymriah from Swiss drugmaker Novartis.
The Central Social Insurance Medical Council, a panel of the Ministry of Health, Labor and Welfare, approved coverage of the treatment, which costs 33.49 million yen ($305,455).
